Advanced search ?

Object

Access Limited

This publication is protected and can be accessed only from certain IPs.
This publication is protected and can be accessed only from certain IPs.

Title: Evaluation of the safety profile of biological drugs used in the treatment of inflammatory bowel diseases

Author:

Moćko, Paweł

Date:

2018

Type:

Praca doktorska

Abstract:

Introduction: Ulcerative colitis (UC) and Crohn disease (CD) are classified as nonspecific inflammatory bowel diseases (IBDs). The aim of the study was to compare the safety profile of biologic drugs in patients with IBDs.Methods: A systematic literature search was performed using PubMed, Embase, and CENTRAL. Randomized controlled trials comparing biologic drugs used in the treatment of patients with UC (infliximab, adalimumab, golimumab, and wedolizumab) or CD (infliximab, adalimumab, wedolizumab, certolizumab pegol, and ustekinumab) with placebo were analyzed. The safety profile of biologic drugs was assessed using a network meta-analysis (NMA). The NMA was performed separately for patients with UC and CD, and generally for patients with IBDs. The study was registered on PROSPERO (CRD42016032607, CRD42016032606, CRD42015029884).Results: For most comparisons and endpoints, the NMA showed no significant differences in the rate of adverse events. A significantly higher risk of injection site reaction was showed for adalimumab compared with placebo (patients with UC) and a significant advantage of certolizumab pegol over infliximab and placebo (patients with IBDs). Conclusion: There were no significant differences in the relative assessment of these drugs or in their safety profile, as compared with placebo.

Place of publishing:

Kraków

Level of degree:

2 - studia doktoranckie

Degree discipline:

choroby układu trawiennego

Degree grantor:

Wydział Nauk o Zdrowiu

Promoter:

Pilc, Andrzej ; Kawalec, Paweł

Date issued:

2017

Identifier:

oai:dl.cm-uj.krakow.pl:4290

Call number:

ZB-128494

Language:

pol; eng

Access rights:

tylko w bibliotece

Subject and keywords:

ulcerative colitis biologic drugs Crohn disease network meta-analysis safety profile

Object collections:

Last modified:

Mar 17, 2023

In our library since:

May 29, 2019

Number of object content hits:

69

Number of object content views in PDF format

1

All available object's versions:

http://dl.cm-uj.krakow.pl:8080/publication/4291

Show description in RDF format:

RDF

Show description in OAI-PMH format:

OAI-PMH

Edition name Date
ZB-128494 Mar 17, 2023

Objects

Similar

Evaluation of the safety profile of biological drugs used in the treatment of inflammatory bowel diseases

Moćko, Paweł

2018
Praca doktorska

The clinical manifestation of inflammatory bowel disease (IBD) in the context of stress and other factors that may cause exacerbation of clinical symptoms

Brzozowski, Bartosz

2018
Praca doktorska

The occurrence of HLA-G antigen and selected markers of inflammation in patients with inflammatory bowel disease

Rozpondek, Piotr

2013
Praca doktorska

Association between short-chain fatty acids, selected inflammatory mediators, and intestinal barrier integrity in patients with inflammatory bowel diseases

Kaczmarczyk, Olga

2023
Praca doktorska

Economic analysis of biologic drugs in the treatment of ulcerative colitis in Poland

Stawowczyk, Ewa

2017
Praca doktorska

Changes in oral cavity in relation to chosen cytokines in saliva from patients with Crohn’s disease

Szczeklik, Katarzyna

2011
Praca doktorska

Magnetic resonance enterography and clinimetric methods in monitoring Lesniowski-Crohn disease treatment in pediatric patients

Herman, Roma

2022
Praca doktorska

Economic Evaluation of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumour Necrosis Factor-alpha Antagonist

Holko, Przemysław

2022
Praca doktorska
More
×

Citation

Citation style:

Contact details

Address

Medical Library
Medyczna 7
30-688 Krakow

Phone

12 658 72 56
517 385 669

E-Mail

Collecting and Elaboration Department
cyfrowabm@cm-uj.krakow.pl

Visit us!

This page uses 'cookies'. More information